ATE222930T1 - Antigene arznei zur behandlung oder vorbeugung - Google Patents

Antigene arznei zur behandlung oder vorbeugung

Info

Publication number
ATE222930T1
ATE222930T1 AT95909582T AT95909582T ATE222930T1 AT E222930 T1 ATE222930 T1 AT E222930T1 AT 95909582 T AT95909582 T AT 95909582T AT 95909582 T AT95909582 T AT 95909582T AT E222930 T1 ATE222930 T1 AT E222930T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
antigenic drug
antigenic
lps
Prior art date
Application number
AT95909582T
Other languages
German (de)
English (en)
Inventor
Christopher Vincent Doidge
Adrian Lee
Fiona Jane Buck
Elizabeth Pietrzykowski
Charles Alexander Quinn
Ian George Barr
Michael John Kleinig
Original Assignee
Csl Ltd
Univ New South Wales
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd, Univ New South Wales filed Critical Csl Ltd
Application granted granted Critical
Publication of ATE222930T1 publication Critical patent/ATE222930T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95909582T 1994-02-21 1995-02-17 Antigene arznei zur behandlung oder vorbeugung ATE222930T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM3995A AUPM399594A0 (en) 1994-02-21 1994-02-21 Antigenic preparation for treatment or prevention of helicobacter infection
PCT/AU1995/000077 WO1995022563A1 (en) 1994-02-21 1995-02-17 Antigenic preparation for treatment or prevention of helicobacter infection

Publications (1)

Publication Number Publication Date
ATE222930T1 true ATE222930T1 (de) 2002-09-15

Family

ID=3778612

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95909582T ATE222930T1 (de) 1994-02-21 1995-02-17 Antigene arznei zur behandlung oder vorbeugung

Country Status (10)

Country Link
US (1) US6663873B2 (cg-RX-API-DMAC7.html)
EP (1) EP0804489B1 (cg-RX-API-DMAC7.html)
JP (1) JPH10500102A (cg-RX-API-DMAC7.html)
KR (1) KR100351534B1 (cg-RX-API-DMAC7.html)
AT (1) ATE222930T1 (cg-RX-API-DMAC7.html)
AU (2) AUPM399594A0 (cg-RX-API-DMAC7.html)
CA (1) CA2182274C (cg-RX-API-DMAC7.html)
DE (1) DE69527986T2 (cg-RX-API-DMAC7.html)
NZ (2) NZ329879A (cg-RX-API-DMAC7.html)
WO (1) WO1995022563A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM399594A0 (en) * 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
JP3635580B2 (ja) * 1994-10-05 2005-04-06 アンテックス バイオロジクス インコーポレーテッド 増強された抗原性ヘリコバクターｓｐ．の作出方法およびそれを含むワクチン
US5681736A (en) * 1994-10-05 1997-10-28 Antex Biologics, Inc. Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
KR19990007828A (ko) 1995-04-21 1999-01-25 피터 터비 헬리코박터 감염 방어 항원
AU693679B2 (en) * 1995-04-21 1998-07-02 Csl Limited Protective helicobacter antigens
AU6583398A (en) * 1997-03-26 1998-10-20 Avant Immunotherapeutics, Inc. Polypeptides which immunoreact with polyclonal antisera against (h. pylori)
GB9715702D0 (en) * 1997-07-24 1997-10-01 Univ Bristol Bacterial isolate
US6599509B2 (en) 1997-09-02 2003-07-29 Massachusetts Institute Of Technology Compositions and methods comprising helicobacter antigens for treatment and prevention of inflammatory bowel disease
WO2002066631A1 (en) * 2001-02-21 2002-08-29 Denka Seiken Co., Ltd. Antibodies recognizing helicobacter pylori and method of detecting helicobacter pylori
DE102004024674A1 (de) * 2004-05-18 2005-12-15 Wolfgang Lorenz Mittel und Verfahren zur Diagnose, Prophylaxe und Therapie von Bindegewebserkrankungen
CN101257919B (zh) 2005-08-05 2012-08-29 国立大学法人德岛大学 可以由选择性产生IgA抗体向产生IgA和IgG两种抗体转换的抗原药物载体和使用该载体的经鼻·粘膜疫苗
AU2014206799B9 (en) 2013-01-17 2018-05-10 Janssen Pharmaceuticals, Inc. MDR E. coli specific antibody
CN106536551B (zh) 2014-02-06 2021-04-16 X4制药(奥地利)有限责任公司 大肠杆菌特异性抗体序列
FI3110441T3 (fi) 2014-02-24 2024-05-06 Glaxosmithkline Biologicals Sa Uusi polysakkaridi ja sen käyttöjä
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
EP3941516A1 (en) 2019-03-18 2022-01-26 Janssen Pharmaceuticals, Inc. Bioconjugates ofe col! o-antigen polysaccharides. methods of production thereof. andmethods of use thereof
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
CN111467368B (zh) * 2020-04-13 2021-05-28 江南大学 含庚糖链的寡糖化合物在制备幽门螺旋杆菌疫苗中的应用
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU644121B2 (en) * 1989-12-04 1993-12-02 Auspharm International Limited Rapid in vitro test for helicobacter pylori using saliva
US5217872A (en) * 1990-02-27 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Method for detection of borrelia burgdorferi antigens
US5098755A (en) * 1990-11-21 1992-03-24 Tanquary Albert C Textured thermoplastic elastomeric film, articles comprising same, and method of making such textured thermoplastic elastomeric film and articles
MX9301706A (es) 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
WO1993022343A1 (en) * 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
US6258359B1 (en) * 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
ATE244578T1 (de) * 1993-07-27 2003-07-15 Csl Ltd Behandlung eines durch helicobakter verursachten gastroduodenalen krankheit
US6406703B1 (en) * 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
US5840302A (en) * 1993-11-10 1998-11-24 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
AUPM399594A0 (en) * 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
AUPM612494A0 (en) * 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
US5681736A (en) * 1994-10-05 1997-10-28 Antex Biologics, Inc. Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
KR19990007828A (ko) * 1995-04-21 1999-01-25 피터 터비 헬리코박터 감염 방어 항원
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
AU3458299A (en) * 1998-03-31 1999-10-18 United States Of America, As Represented By The Secretary Of Agriculture, The Monoclonal antibodies against (campylobacter jejuni) and (campylobacter coli) outer membrane antigens
JP2002518343A (ja) * 1998-06-19 2002-06-25 メリウクス オラバクス ヘリコバクター感染に対する非経口的免疫処置法におけるｌｔおよびｃｔ

Also Published As

Publication number Publication date
AU1801195A (en) 1995-09-04
EP0804489A1 (en) 1997-11-05
KR100351534B1 (ko) 2003-03-15
KR970701209A (ko) 1997-03-17
AU693864B2 (en) 1998-07-09
US20020122794A1 (en) 2002-09-05
AUPM399594A0 (en) 1994-03-17
US6663873B2 (en) 2003-12-16
EP0804489A4 (cg-RX-API-DMAC7.html) 1997-11-19
NZ329879A (en) 1999-10-28
NZ281146A (en) 1998-04-27
CA2182274A1 (en) 1995-08-24
JPH10500102A (ja) 1998-01-06
CA2182274C (en) 2007-05-22
WO1995022563A1 (en) 1995-08-24
EP0804489B1 (en) 2002-08-28
DE69527986D1 (de) 2002-10-02
DE69527986T2 (de) 2003-04-10
HK1004677A1 (en) 1998-12-04

Similar Documents

Publication Publication Date Title
ATE222930T1 (de) Antigene arznei zur behandlung oder vorbeugung
ATE279940T1 (de) Behandlung und prävention von helicobacter- infektionen
AU1199900A (en) Use of purified invaplex from gram negative bacteria as a vaccine
IL153474A0 (en) Human papilloma virus treatment
GB2303854B (en) Helicobacter proteins and vaccines
DK0865297T3 (da) Vaccinesammensætninger til intranasal administration omfattende chitosan og anvendelsen deraf
AU7814498A (en) Multivalent (in ovo) avian vaccine
EP0716613A4 (en) TREATING A GASTRODUODENAL DISEASE CAUSED BY -i (HELICOBAKTER PYLORI)
MY122216A (en) New vaccine and method of use
DK0484438T3 (da) Biologisk præparat og dets anvendelse
DK0787135T3 (da) Vandopløslige derivater af epipodophyllotoxin, fremgangsmåde til fremstilling deraf og anvendelse som et lægemiddel til beh
EP0274496A4 (en) PREPARATION AND METHOD FOR IMMUNOLOGICAL CASTERING AND STERILIZATION.
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
LU90378I2 (fr) Tetravac
EP0090660A3 (en) Neisseria gonorrhoeae vaccine
AU6435596A (en) Pasteurella haemolytica type A-1 bacterin-toxoid vaccine
FI971402A0 (fi) Menetelmä voimistettujen antigeenisten Helico-bacter-lajien ja niitä sisältävien rokotteiden valmistamiseksi
DK0809653T3 (da) Helicobacter pylori-antigen
ATE71299T1 (de) Pharmazeutische zubereitung zur behandlung bakterieller infektionen.
CA2191440A1 (en) Treatment and prevention of helicobacter infection
NZ331674A (en) Use of antigenic preparations comprising Helicobacter catalase for treating or preventing Helicobacter infection
NL300026I1 (nl) Varkenscholeravirusvaccin en diagnosticum.
MX9700215A (es) Proteinas y vacunas de helicobacter.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties